PEGylated Proteins Market

Table of Contents

1 Introduction (Page No. - 10)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered in the Report
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 14)
    2.1 Market Size Estimation
    2.2 Market Breakdown and Data Triangulation
    2.3 Market Share Estimation
           2.3.1 Key Data From Secondary Sources
           2.3.2 Key Data From Primary Sources
           2.3.3 Assumptions for the Study

3 Executive Summary (Page No. - 21)
    3.1 Introduction
    3.2 Current Scenario
    3.3 Future Outlook
    3.4 Conclusion

4 Premium Insights (Page No. - 28)
    4.1 Global PEGylated Proteins Market Overiew
    4.2 PEGylated Proteins Market: By End-User & Region
    4.3 PEGylated Proteins Market: Geographic Snapshot
    4.4 Life Cycle Analysis, By Region (2016)

5 Industry Insights (Page No. - 32)
    5.1 Introduction
    5.2 Market Indicators
           5.2.1 Increasing R&D Spending in Pharmaceutical and Biotechnology Sector
    5.3 Strategic Benchmarking
           5.3.1 Agreement & Collaboration
    5.4 Porter’s Five Forces Analysis
           5.4.1 Threat From New Entrants
           5.4.2 Threat From Substitutes
           5.4.3 Bargaining Power of Suppliers
           5.4.4 Bargaining Power of Buyers
           5.4.5 Intensity of Competitive Rivalry
    5.5 Regulatory Scenario
    5.6 Pipeline Analysis

6 Global PEGylation of Proteins Market, Overview (Page No. - 41)
    6.1 Introduction
    6.2 Market Dynamics
           6.2.1 Drivers
                     6.2.1.1 Increase in R&D Spending
                     6.2.1.2 Growth in Biologics Sector to Propel the PEGylated Proteins Market
                     6.2.1.3 Increase in Adoption of Protein-Based Drugs Over Non-Protein-Based Drugs
                     6.2.1.4 Increasing Protein’s Stability and Circulating Half-Life
                     6.2.1.5 High Prevalence Rate of Lifestyle Diseases
           6.2.2 Restraints
                     6.2.2.1 Drug Failure and Recalls Hinders Market Growth
           6.2.3 Opportunities
                     6.2.3.1 Rising Opportunities in Emerging Markets
                     6.2.3.2 Top-Selling Biologics Drugs Going Off–Patent in the Near Future
           6.2.4 Challenge
                     6.2.4.1 Increasing Market Consolidation Increases Entry  Barriers and Restraints Market Growth

7 PEGylated Proteins Market, By Product (Page No. - 48)
    7.1 Introduction
    7.2 Consumbales
           7.2.1 Pegylation Kits
           7.2.2 Pegylation Reagents
                     7.2.2.1 Monofunctional Linear Pegs
                     7.2.2.2 Bifunctional Pegs
                     7.2.2.3 Multi-Arm Pegs
                     7.2.2.4 Branched Pegs
                     7.2.2.5 Other Pegylation Reagents
    7.3 Services
           7.3.1 Development of PEGylated Biosimilars
           7.3.2 Process Development of Peg-Drug Conjugate Manufacturing
           7.3.3 Pilot Production of Peg Drug Conjugate
           7.3.4 Development of Analytical Methods
           7.3.5 Pegylation Feasibility Studies

8 PEGylated Proteins Market, By Protein Type (Page No. - 66)
    8.1 Key Findings
    8.2 Introduction
    8.3 Colongy Stimulating Factors
    8.4 Interferons
    8.5 Erythropoietin (EPO)
    8.6 Recombinant Factor Viii
    8.7 Monoclonal Antibodies
    8.8 Other Protein Type

9 PEGylated Proteins Market, By Application (Page No. - 77)
    9.1 Key Findings
    9.2 Introduction
    9.3 Cancer Treatment
    9.4 HEPAtitis
    9.5 Chronic Kidney Disease
    9.6 Hemophilia
    9.7 Multiple Sclerosis
    9.8 Gastrointestinal Disorder
    9.9 Other Application

10 Global PEGylation of Proteins Market, By End-User (Page No. - 89)
     10.1 Key Findings
     10.2 Introduction
     10.3 Pharmaceutical & Biotechnology Companies
     10.4 Contract Research Organization
     10.5 Academic Research Institutes

11 PEGylated Proteins Market, By Region (Page No. - 96)
     11.1 Introduction
     11.2 North America
               11.2.1 U.S.
               11.2.2 Canada
     11.3 Europe
     11.4 Asia
     11.5 Rest of the World

12 Global PEGylation of Proteins Market, Competitive Landscape (Page No. - 135)
     12.1 Introduction
     12.2 Strategic Analysis
     12.3 Market Share Analysis
     12.4 Competitive Situation and Trends
               12.4.1 Agreements & Collaboration
               12.4.2 New Product Launches and Product Showcase
               12.4.3 Acquisitions
               12.4.4 Product Upgradation

13 Company Profiles (Page No. - 142)
     13.1 Introduction
     13.2 Merck Millipore
               13.2.1 Business Overview
               13.2.2 Products Offered
               13.2.3 Recent Developments
               13.2.4 MnM View
                           13.2.4.1 Financial Analysis
                           13.2.4.2 Strategic Analysis
     13.3 Thermo Fisher Scientific Inc.
               13.3.1 Business Overview
               13.3.2 Products Offered
               13.3.3 Recent Developments
               13.3.4 MnM View
                           13.3.4.1 Financial Analysis
                           13.3.4.2 Strategic Analysis
     13.4 NOF American Corporation (A Subsidiary of NOF Corporation)
               13.4.1 Business Overview
               13.4.2 Products Offered
               13.4.3 Recent Developments
               13.4.4 MnM View
                           13.4.4.1 Financial Analysis
                           13.4.4.2 Strategic Analysis
     13.5 Jenkem Technology
               13.5.1 Business Overview
               13.5.2 Products Offered
               13.5.3 Recent Developments
                           13.5.3.1 Strategic Analysis
     13.6 Creative Pegworks
               13.6.1 Business Overview
               13.6.2 Products Offered
               13.6.3 Recent Developments
     13.7 Celares GmbH
               13.7.1 Business Overview
               13.7.2 Products Offered
               13.7.3 Recent Developments
     13.8 Quanta Biodesign, Ltd
               13.8.1 Business Overview
               13.8.2 Products Offered
               13.8.3 Recent Developments
     13.9 Biomatrik, Inc.
               13.9.1 Business Overview
               13.9.2 Products Offered
               13.9.3 Recent Developments
     13.10 Iris Biotech GmbH
               13.10.1 Business Overview
               13.10.2 Products Offered
               13.10.3 Recent Developments
     13.11 Laysan Bio, Inc.
               13.11.1 Business Overview
               13.11.2 Products Offered
               13.11.3 Recent Developments

14 Appendix (Page No. - 168)
     14.1 Insights of Industry Experts
     14.2 Discussion Guide
     14.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
     14.4 Introducing RT: Real-Time Market Intelligence
     14.5 Available Customizations
     14.6 Related Reports

List of Tables (87 Tables)

Table 1 PEGylated Proteins Market Summary
Table 2 PEGylation of Proteins Market Size, By Product, 2014–2021 (USD Million)
Table 3 Market Size for Consumables, By Type, 2014–2021 (USD Million)
Table 4 Market Size for Consumables, By Region, 2014–2021 (USD Million)
Table 5 North America: Market Size for Consumables, By Region, 2014–2021 (USD Million)
Table 6 Market Size for Pegylation Kits, By Region, 2014–2021 (USD Million)
Table 7 North America: Market Size for Pegylation Kits, By Region, 2014–2021 (USD Million)
Table 8 Market Size for Pegylation Reagents, By Region, 2014–2021 (USD Million)
Table 9 North America: Market Size for Pegylation Reagents, By Region, 2014–2021 (USD Million)
Table 10 Market Size for Services, By Region, 2014–2021 (USD Million)
Table 11 North America: Market Size for Services, By Region, 2014–2021 (USD Million)
Table 12 Market Size for Development of PEGylated Biosimilars, By Region, 2014–2021 (USD Million)
Table 13 North America: Market Size for Development of PEGylated Biosimilars, By Region, 2014–2021 (USD Million)
Table 14 PEGylation of Proteins Market Size for Process Development of Peg-Conjugate Manufactuirng , By Region, 2014–2021 (USD Million)
Table 15 North America: Market Size for Process Development of Peg-Conjugate Manufactuirng, By Region, 2014–2021 (USD Million)
Table 16 Market Size for Pilot Production of Peg Drug Conjugate, By Region, 2014–2021 (USD Million)
Table 17 North America: Market Size for Pilot Production of Peg Drug Conjugate, By Region, 2014–2021 (USD Million)
Table 18 Market Size for Development of Analytical Methods, By Region, 2014–2021 (USD Million)
Table 19 North America: Market Size for Development of Analytical Methods, By Region, 2014–2021 (USD Million)
Table 20 Market Size for PEGylation Feasibility Studies , By Region, 2014–2021 (USD Million)
Table 21 North America: Market Size for PEGylation Feasibility Studies, By Region, 2014–2021 (USD Million)
Table 22 Colony Stimulating Factors Market Size, By Protein Type, 2014–2021 (USD Million)
Table 23 Market Size for Colony Stimulating Factors, By Region, 2014–2021 (USD Million)
Table 24 North America: Market Size for Colony Stimulating Factors, By Region, 2014–2021 (USD Million)
Table 25 Market Size for Interferon, By Region, 2014–2021 (USD Million)
Table 26 North America: Market Size for Interferon, By Region, 2014–2021 (USD Million)
Table 27 Market Size for Erythropoietin, By Region, 2014–2021 (USD Million)
Table 28 North America: Market Size for Erythropoietin, By Region, 2014–2021 (USD Million)
Table 29 PEGylation of Proteins Market Size for Recombinant Factor Viii, By Region, 2014–2021 (USD Million)
Table 30 North America: Market Size for Recombinant Factor Viii, By Region, 2014–2021 (USD Million)
Table 31 Market Size for Monoclonal Antibodies, By Region, 2014–2021 (USD Million)
Table 32 North America: Market Size for Monoclonal Antibodies, By Region, 2014–2021 (USD Million)
Table 33 Market Size for Other Protein Type, By Region, 2014–2021 (USD Million)
Table 34 North America: PEPylated Proteins Market Size for Other Protein Type, By Region, 2014–2021 (USD Million)
Table 35 Cancer Treatment Market Size, By Application, 2014–2021 (USD Million)
Table 36 Market Size for Cancer Treatment, By Region, 2014–2021 (USD Million)
Table 37 North America: Market Size for Cancer Treatment, By Region, 2014–2021 (USD Million)
Table 38 Market Size for Hepatitis, By Region, 2014–2021 (USD Million)
Table 39 North America: Market Size for Hepatitis, By Region, 2014–2021 (USD Million)
Table 40 Market Size for Chronic Kidney Disease, By Region, 2014–2021 (USD Million)
Table 41 North America: PEGylation of Proteins Market Size for Chronic Kidney Disease, By Region, 2014–2021 (USD Million)
Table 42 Market Size for Hemophilia, By Region, 2014–2021 (USD Million)
Table 43 North America: Market Size for Hemophilia, By Region, 2014–2021 (USD Million)
Table 44 Market Size for Multiple Sclerosis, By Region, 2014–2021 (USD Million)
Table 45 North America: Market Size for Multiple Sclerosis, By Region, 2014–2021 (USD Million)
Table 46 Market Size for Gastrointestinal Disorder, By Region, 2014–2021 (USD Million)
Table 47 North America: Market Size for Gastrointestinal Disorder , By Region, 2014–2021 (USD Million)
Table 48 Market Size for Other Applications, By Region, 2014–2021 (USD Million)
Table 49 North America: Market Size for Other Application, By Region, 2014–2021 (USD Million)
Table 50 Market Size, By End-User, 2014–2021 (USD Million)
Table 51 Market Size for Pharmaceutical & Biotechnology Companies Segment, By Region, 2014–2021 (USD Million)
Table 52 North America: Market Size for Pharmaceutical & Biotechnology Companies , By Region, 2014–2021 (USD Million)
Table 53 Market Size for Contract Research Organizations Segment, By Region, 2014–2021 (USD Million)
Table 54 North America: Market Size for Contract Research Organizations, By Region, 2014–2021 (USD Million)
Table 55 PEGylated Proteins Market Size for Academic Research Institutes, By Region, 2014–2021 (USD Million)
Table 56 North America: Market Size for Academic Research Institutes, By Region, 2014–2021 (USD Million)
Table 57 Market Size, By Region, 2014–2021 (USD Million)
Table 58 North America: PEGylated Proteins Market Size, By Region, 2014–2021 (USD Million)
Table 59 North America: Market Size, By Product, 2014–2021 (USD Million)
Table 60 North America: Market Size, By Protein Type, 2014–2021 (USD Million)
Table 61 North America: Market Size, By Application, 2014–2021 (USD Million)
Table 62 North America: Market Size, By End User, 2014–2021 (USD Million)
Table 63 U.S: Market Size, By Product, 2014–2021 (USD Million)
Table 64 U.S: Market Size, By Protein Type, 2014–2021 (USD Million)
Table 65 U.S: Market Size, By Application, 2014–2021 (USD Million)
Table 66 U.S: Market Size, By End User, 2014–2021 (USD Million)
Table 67 Canada: PEGylated Proteins Market Size, By Product, 2014–2021 (USD Million)
Table 68 Canada: Market Size, By Protein Type, 2014–2021 (USD Million)
Table 69 Canada: Market Size, By Application, 2014–2021 (USD Million)
Table 70 Canada: Market Size, By End User, 2014–2021 (USD Million)
Table 71 Europe: Market Size, By Product, 2014–2021 (USD Million)
Table 72 Europe: Market Size, By Protein Type, 2014–2021 (USD Million)
Table 73 Europe: Market Size, By Application, 2014–2021 (USD Million)
Table 74 Europe: Market Size, By End User, 2014–2021 (USD Million)
Table 75 Asia: PEGylated Proteins Market Size, By Product, 2014–2021 (USD Million)
Table 76 Asia: Market Size, By Protein Type, 2014–2021 (USD Million)
Table 77 Asia: Market Size, By Application, 2014–2021 (USD Million)
Table 78 Asia: Market Size, By End User, 2014–2021 (USD Million)
Table 79 RoW: Market Size, By Product, 2014–2021 (USD Million)
Table 80 RoW: Market Size, By Protein Type, 2014–2021 (USD Million)
Table 81 RoW: Market Size, By Application, 2014–2021 (USD Million)
Table 82 RoW: Market Size, By End User, 2014–2021 (USD Million)
Table 83 Market Developments Between January 2013 and May 2016
Table 84 Agreements & Collaborations, 2013–2016
Table 85 New Product Launches and Product Showcase, 2013–2016
Table 86 Acquisitions, 2013–2016
Table 87 Product Upgradation, 2013–2016
 
 
List of Figures (65 Figures)
 
Figure 1 PEGylated Proteins Market
Figure 2 Research Design
Figure 3 Global Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 PEGylated Proteins Market Size Estimation Methodology: Top-Down Approach
Figure 5 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 6 Data Triangulation Methodology
Figure 7 PEGylation of Proteins Market Size, By Product, 2016 vs 2021 (USD Million)
Figure 8 Global Market Size, By Protein Type, 2016 vs 2021 (USD Million)
Figure 9 Market Size, By Application, 2016 vs 2021 (USD Million)
Figure 10 Market Size, By End-User, 2016 vs 2021 (USD Million)
Figure 11 PEGylated Proteins Market, By Region, 2016 (USD Million)
Figure 12 Market Size, By Region, 2016 vs 2021 (USD Million)
Figure 13 Increase in R&D Spending to Drive Market Growth
Figure 14 Pharmaceutical & Biotechnology Companies to Command the Largest Market Share in 2016
Figure 15 Asia to Register Highest Growth During the Forecast Period
Figure 16 Asia Holds Lucrative Growth Opportunities in the PEGylated Proteins Market
Figure 17 Increasing R&D Investments in Pharma Industry Boosting the Growth of the Global Market
Figure 18 Market Leaders Adopted the Inorganic Growth Strategy of Agreement & Collaboration
Figure 19 Porter’s Five Forces Analysis (2016)
Figure 20 Increase in R&D Spending Will Drive the Global Market
Figure 21 Patent Application By Region, 2013
Figure 22 Consumables Segment Commands the Largest Share of the PEGylated Proteins Market in 2016
Figure 23 Pegylation Kits Segment Commands the Largest Share of the Consumables Market in 2016
Figure 24 Pegylation Reagents, By Type
Figure 25 Development of PEGylated Biosimilars Segment Commands the Largest Share of the Services Market in 2016
Figure 26 Colony Stimulating Factors to Command the Largest Share of the PEGylated Proteins Type Market in 2016
Figure 27 Cancer Treatment to Command the Largest Share of the PEGylated Protein Application Market in 2016
Figure 28 Pharmaceutical & Biotechnology Companies to Command the Largest Share of the PEGylated Proteins End-User Market in 2016
Figure 29 PEGylated Proteins Market Segmentation, By Region: Market Size and Growth Rate, 2016-2021
Figure 30 Asian Market for PEGylated Proteins Expected to Grow at the Highest Rate (2016 to 2021)
Figure 31 North America: Market Snapshot
Figure 32 Canada to Grow at the Highest Rate in North America
Figure 33 Consumables, the Largest Product Segment in North America
Figure 34 Colony Stimulating Factors Protein Type Segment Dominates the North American PEGylated Proteins Market
Figure 35 Cancer Treatment, the Largest Application Segment in North America
Figure 36 Pharmaceutical & Biotechnology Companies Segment Commands Largest Share of the North American Market
Figure 37 Consumables, the Largest Product Segment in U.S
Figure 38 Colony Stimulating Factors Protein Type Segment Dominates the U.S PEGylated Proteins Market
Figure 39 Cancer Treatment, the Largest Application Segment in U.S
Figure 40 Pharmaceutical & Biotechnology Companies Segment Commands Largest Share of the U.S Market
Figure 41 Consumables, the Largest Product Segment in Canada
Figure 42 Colony Stimulating Factors Protein Type Segment Dominates the Canada Market
Figure 43 Cancer Treatment, the Largest Application Segment in Canada
Figure 44 Pharmaceutical & Biotechnology Companies Segment Commands Largest Share of the Canada Market
Figure 45 Europe: PEGylated Proteins Market Snapshot (2016)
Figure 46 Consumables, the Largest Product Segment in Europe
Figure 47 Colony Stimulating Factors Type Segment Dominates the European Market
Figure 48 Cancer Treatment, the Largest Application Segment in Europe
Figure 49 Pharmaceutical & Biotechnology Companies Segment Commands Largest Share of the European Market
Figure 50 Asia: PEGylated Proteins Market Snapshot
Figure 51 Consumables, the Largest Product Segment in Asia
Figure 52 Colony Stimulating Factors Protein Type Segment Dominates the Asia Market
Figure 53 Cancer, the Largest Application Segment in Asia
Figure 54 Pharmaceutical & Biotechnology Companies Segment Commands Largest Share of the Asia Market
Figure 55 RoW: PEGylated Proteins Market Snapshot (2016)
Figure 56 Consumables, the Largest Product Segment in RoW
Figure 57 Colony Stimulating Factors Protein Type Segment Dominates the RoW Market
Figure 58 Cancer Treatment, the Largest Application Segment in RoW
Figure 59 Pharmaceutical & Biotechnology Companies Segment Commands Largest Share of the RoW Market
Figure 60 Key Developments in the PEGylated Proteins Market, 2013–2016
Figure 61 PEGylated Proteins Market Share Analysis, By Key Player, 2016
Figure 62 Financial Performances of the Leading Market Players
Figure 63 Company Snapshot: Merck Millipore
Figure 64 Thermo Fisher Scientific: Company Snapshot
Figure 65 Company Snapshot: NOF American Corporation (A Subsidiary of NOF Corporation)